Low dose α interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial

Gut

Volumn 38, Issue 4, 1996, Pages 603-609

  Sanchez Tapias J M ^a,g   Forns, X ^a   Ampurdanes S ^a   Tito L ^a,b   Planas, R ^c   Viver, J M ^d   Acero, D ^e   Torres, M ^b   Mas, P ^f   Morillas, R ^c   Forne M ^d   Espinos J ^f   Llovet, J M ^c   Costa, J ^a   Olmedo, E ^a   Lopez Labrador F X ^a   Jimenez De Anta M T ^a   Rodes J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DE L ESPERIT SANT   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL MÚTUA DE TERRASSA   (Spain)

^e HOSPITAL JOSEP TRUETA   (Spain)

^f Hospital Parc Tauli   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

Author keywords

Hepatitis C therapy; Hepatitis C virus; Interferon

Indexed keywords

ALPHA INTERFERON;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 9244227972     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.38.4.603     Document Type: Article

References (50)

1. Sánchez-Tapias JM, Barrera JM, Costa J, Ercilla MG, Parés A, Comalrrena LI, et al. Hepatitis C virus infection in non-alcoholic chronic liver diseases. Ann Intern Med 1990; 112: 921-4.
2. Jeffers LJ, Hasan F, de Medina M, Reddy R, Parker T, Silva M, et al. Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis. Hepatology 1992; 15: 187-90.
3. Hosoda K, Omata M, Yokosuka O, Kato N, Ohto M. Non-A, non-B chronic hepatitis is chronic hepatitis C: a sensitive assay for detection of hepatitis C virus RNA in the liver. Hepatology 1992; 15: 777-81.
4. Hopf U, Möller B, Küter D, Stemerowicz R, Lobeck H, Lüdtke-Handjery, et al. Long-term follow up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol 1990; 10: 69-76.
5. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, et al. Long term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992; 16: 273-81.
6. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14: 969-74.
7. Kiyosawa K, Akahane Y, Nagata A, Furata S. Hepatocellular carcinoma after non-A, non-B posttransfusion hepatitis. Am J Gastroenterol 1984; 79: 777-81.
8. Shindo M, DiBisceglie AM, Cheung L, Shih WK, Cristiano K, Feinstone SM, et al. Decrease in serum hepatitis C virus RNA during alpha interferon therapy for chronic hepatitis C. Ann Intern Med 1991; 115: 700-4.
9. Chayama K, Saitoh S, Arase Y, Ikeda K, Matsumoto T, Sakai Y, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991; 13: 1040-3.
10. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology 1993; 104: 877-83.
11. David E, Pucci A, Palladin D, Saracco G, Garello E, Pintus C, et al. Histologic changes in liver biopsy specimens produced by recombinant interteron alpha-2b therapy for chronic non-A, non-B viral hepatitis. A randomized controlled trial. Am J Clin Pathol 1992; 98: 397-401.
12. Marcellin P, Boyer N, Martinot-Peignoux M, Areias J, Giostra E, Degott C, et al. Long-term histological improvement and persistent HCV replication in patients with chronic hepatitis C having responded to recombinant alpha interferon. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral hepatitis and liver disease. Tokyo: Springer-Verlag, 1994: 635-7.
13. Romeo R, Pol S, Berthelot P, Brechot C. Eradication of hepatitis C virus RNA after alpha-interferon therapy. Ann Intern Med 1994; 121: 276-7.
14. Janssen HLA, Brouwer JT, Nevens F, Sánchez-Tapias JM, Craxi A, Hadzyannis SJ. Fatal hepatic decompensation associated with interferon alpha. BMJ 1993; 306: 107-8.
15. Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989; 9: 273-7.
16. Davis GL, Ballart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicentre randomized controlled trial. N Engl J Med 1989; 321: 1501-6.
17. Causse X, Godinot H, Ouzan D, Chevalier M, Chossegros P, Zoulim F, et al. Comparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991; 101: 497-502.
18. Marcellin P, Boyer N, Giostra E, Degott C, Couroucé AM, Degos F, et al. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicentre randomized controlled trial from France. Hepatology 1991; 13: 393-7.
19. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon α-2b. Hepatology 1993; 18: 1300-5.
20. Reichen J, Solioz M, Buhler H, Gonvers JJ, Knoblauch M, Lavanchy D, et al. Low-dose interferon in chronic non-A, non-B hepatitis: effects on quantitative liver function and structure in a randomized, controlled, multicentre trial. Clin Investig 1993; 71: 888-93.
21. Varagona G, Brown D, Kibbler H, Scheuer P, Ashrafzadeh P, Sherlock S, et al. Response, relapse and re-treatment rates and viremia in chronic hepatitis C treated with α-2b interferon alpha: A phase III study. European Journal of Gastroenterology and Hepatology 1992; 4: 701-12.
22. Kagawa T, Morizane T, Saito H, Miyaguchi S, Tsunematsu S, Tada S, et al. A randomized, controlled trial of lymphoblastoid interferon in patients with chronic hepatitis C. J Hepatol 1993; 17: 91-6.
23. Simmonds P, Rose KA, Graham S, Chan SW, Lin CK, McOmish F, et al. Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV type 1, 2 and 3. J Clin Microbiol 1993; 31: 1493-503.
24. Simmonds P, Zhang LQ, Watson HG, Rebus L, Ferguson ED, Balfe P, et al. Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users. Lancet 1990; 336: 1469-72.
25. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Ann Biochem 1987; 162: 156-9.
26. Garson JA, Ring C, Tuke P, Tedder RS. Enhanced detection bv PCR of hepatitis C virus RNA [Letter]. Lancet 1990; 336: 878-9.
27. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha-interferon. A preliminary report. N Engl J Med 1986; 315: 1575-8.
28. Tińe F, Magrin S, Craxí A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomized clinical trials. J Hepatol 1991; 13: 192-9.
29. Iino S, Yasuda K, Sainokami S, Hino K. Treatment of chronic hepatitis C with interferon-α. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral hepatitis and liver disease. Tokyo: Springer-Verlag, 1994: 607-9.
30. Davis GL. Prediction of response to interferon treatment in chronic hepatitis C. J Hepatol 1994; 21: 1-3.
31. Jouët P, Roudot-Thoraval F, Dhumeaux D, Métreau JM, and Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB-C. Comparative efficacy of interferon alfa in cirrhotic and non-cirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994; 106: 686-90.
32. Pagliaro L, Craxí A, Cammaá C, Tiné F, Di Marco V, Lo Iacomo O, et al. Interferon-α for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994; 19: 820-8.
33. Pérez R, Pravia R, Linares A, González M, Rodríguez M, Lombraña JLS, et al. Treatment of chronic hepatitis C with recombinant interferon alfa-2b for nine months. Gut 1992; 34 (suppl): S136-8.
34. Serfati L, Giral P, Loria A, Andreani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994; 21: 12-7.
35. Weiland O, Schvarcz R, Wejstal R, Norkrans G, Fryden A. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience. J Hepatol 1990; 11 (suppl 1): S57-62.
36. Battezzati PM, Podda M, Bruno S, Zuin M, Crosignani A, Camisasca M, et al. Factors predicting early response to treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis. Preliminary report of a long term trial. Ital J Gastroenterol 1992; 24: 481-4.
37. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh I, Takayanagi M, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-9.
38. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-94.
39. Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994; 39: 977-82.
40. Chemello L, Pontiso P, Rose KA, Simmonds P, Bonetti P, Cavalletto L, et al. The long-term response (LTR) to interferon-alfa (IFN-2A) in chronic hepatitis C is influenced by dose and duration of treatment and the HCV serotype [Abstract]. J Hepatol 1993; 18 (suppl 1): S10.
41. Bellobuono A, Mondazzi L, Tempini S, Bellati G, Cassará L, Lombino M, et al. Efficacy of different regimens of α-interferon in chronic hepatitis C and relationship between response and HCV genotype [Abstract]. J Hepatol 1994; 21 (suppl 1): S35.
42. Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, et al. High sustained response rate and clearance of viremia after treatment with interferon-alpha 2b for 60 weeks. Hepatology 1994; 19: 280-5.
43. Bosch O, Tapia L, Quiroga JA, Carreño V. An escalating dose regime of recombinant interferon-alpha-2A in the treatment of chronic hepatitis C. J Hepatol 1993; 17: 146-9.
44. Camps J, Crisóstomo S, García-Granero M, Riezu-Boj JI, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut 1993; 34: 1714-7.
45. Chemello L, Alberti A, Rose K, Simmonds P. Hepatitis C serotype and response to interferon therapy [Letter]. N Engl J Med 1994; 330: 143.
46. Dusheiko G, Alberti A, Colombo M, Craxi A, Frost C, Prieto J, et al. The influence of serotypes of hepatitis C virus on sustained response to alpha interferon treatment [Abstract]. J Hepatol 1994; 21 (suppl 1): S17.
47. Ampurdanés S, Vilella A, Olmedo E, Maluenda MD, López-Labrador FX, Costa J, et al. Hepatitis C virus serotype and response to interferon in chronic hepatitis C [Abstract]. J Hepatol 1994; 21 (suppl 1): S23.
48. Suzuki T, Tanaka E, Matsumoto A, Urushihara A, Sodeyama T. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis to interferon-α2a therapy. J Med Virol 1995; 46: 162-8.
49. Davis GL, Lau JY, Urdea MS, Neuwald PD, Wilber JC, Lindsay K, et al. Quantitative detection of hepatitis C virus (HCV) RNA by a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon treated patients. Hepatology 1994; 19: 1337-41.
50. Olmedo E, Forns X, Ampurdanés S, Maluenda MD, López-labrador FX, Costa J, et al. Evaluacion de la replicación del virus de la hepatitis C (VHC), su relación con el genotipo viral, la gravedad de la enfermedad y la respuesta al tratamiento [Abstract]. Gastroenterol Hepatol 1995; 18: 266.